| |
CNRIP1
|
FBN1
|
INA
|
MAL
|
SNCA
|
Panel
|
|---|
| |
M
|
U
|
M
|
U
|
M
|
U
|
M
|
U
|
M
|
U
|
Pos
|
Neg
|
|---|
|
Tumors
| | | | | | | | | | | | |
|
No
|
169/179
|
10/179
|
142/179
|
37/179
|
117/179
|
62/179
|
162/179
|
17/179
|
119/179
|
60/179
|
168/179
|
11/179
|
|
Tumor phenotype
| | | | | | | | | | | | |
|
MSI
|
47
|
1
|
42
|
6
|
36
|
11
|
46
|
2
|
37
|
10
|
47
|
1
|
|
MSS
|
122
|
9
|
100
|
31
|
81
|
51
|
116
|
15
|
82
|
50
|
121
|
10
|
|
P value
|
NS
|
NS
|
7.4E-2
|
NS
|
7.6E-2
|
NS
|
|
BRAF
ex15
| | | | | | | | | | | | |
|
Wild Type
|
136
|
10
|
109
|
37
|
87
|
59
|
129
|
17
|
89
|
57
|
135
|
11
|
|
Mutation
|
33
|
0
|
33
|
0
|
30
|
3
|
33
|
0
|
30
|
3
|
33
|
0
|
|
P value
|
NS
|
2.5E-4
|
4.5E-4
|
3.9E-2
|
8.5E-4
|
NS
|
|
Sex
| | | | | | | | | | | | |
|
Male
|
83
|
6
|
71
|
18
|
57
|
32
|
81
|
8
|
57
|
32
|
81
|
8
|
|
Female
|
86
|
4
|
71
|
19
|
60
|
30
|
81
|
9
|
62
|
28
|
87
|
3
|
|
P value
|
NS
|
NS
|
NS
|
NS
|
NS
|
NS
|
|
Tumor site - 2 groups
| | | | | | | | | | | | |
|
Proximal
|
67
|
3
|
57
|
13
|
53
|
17
|
65
|
5
|
50
|
20
|
66
|
4
|
|
Distal
|
100
|
7
|
83
|
24
|
63
|
44
|
95
|
12
|
67
|
40
|
100
|
7
|
|
P value
|
NS
|
NS
|
2.4E-2
|
NS
|
NS
|
NS
|
|
Tumor site - 3 groups
| | | | | | | | | | | | |
|
Right
|
67
|
3
|
57
|
13
|
53
|
17
|
65
|
5
|
50
|
20
|
66
|
4
|
|
Left
|
57
|
0
|
48
|
9
|
36
|
21
|
54
|
3
|
39
|
18
|
57
|
0
|
|
Rectum
|
43
|
7
|
35
|
15
|
27
|
23
|
41
|
9
|
28
|
22
|
43
|
7
|
|
P value
|
6.1E-3
|
NS
|
4.3E-2
|
5.5E-2
|
NS
|
1.1E-2
|
|
Stage
| | | | | | | | | | | | |
|
I
|
27
|
3
|
23
|
7
|
19
|
11
|
26
|
4
|
20
|
10
|
27
|
3
|
|
II
|
76
|
3
|
60
|
19
|
54
|
25
|
72
|
7
|
52
|
27
|
75
|
4
|
|
III
|
45
|
4
|
42
|
7
|
31
|
18
|
44
|
5
|
33
|
16
|
45
|
4
|
|
IV
|
21
|
0
|
17
|
4
|
13
|
8
|
20
|
1
|
14
|
7
|
21
|
0
|
|
P value
|
NS
|
NS
|
NS
|
NS
|
NS
|
NS
|
- Pearson's chi-square and Fisher's exact tests were used to calculate P-values. Associations between SPG20 promoter hypermethylation and tumor phenotype have been published elsewhere [9].
- Abbreviations: MSI, microsatellite instability; MSS, microsatellite stable; Neg, biomarker panel negative; NS, not significant; Pos, biomarker panel positive. A positive biomarker panel is defined as methylation of two or more of the following biomarkers: CNRIP1, FBN1, INA, MAL, SNCA and SPG20.
